Japan-based NS Pharma filed for FDA approval Oct. 2 for its Duchenne muscular dystrophy treatment, dealing another blow to Sarepta, whose Duchenne drug was rejected by the FDA in August.

Not only are gene therapies expensive, they are physically out of reach for many patients, according to a PwC Health Research Institute report.

Civica Rx's first medication was given to patients at a Utah hospital Oct. 2.

Johnson & Johnson has agreed to pay $20.4 million to avoid the first federal trial that accuses the drugmaker of fueling the opioid epidemic.

Compared to small chain pharmacies, retail pharmacy giants like CVS Pharmacy and Walgreens offered the lowest cash price for generic drugs according to data published Oct. 1.

Mallinckrodt changed its severance package policy in a move that could indicate it's preparing for a change in ownership structure, according to The Wall Street Journal.

Novant Health, a 15-hospital system in Winston-Salem, N.C., will open retail health clinics inside several Walgreens pharmacies in the state.

Biogen appointed two members to its senior leadership team after its research and development chief stepped down, according to an Oct. 1 news release.

The Senate's budget package that passed Sept. 26 included legislation that increases the amount drugmakers must pay in rebates for Medicaid. The legislation was signed into law by the president Sept. 27.

Healthcare is not just about taking care of patients. It’s also about taking care of your staff.